What is Entera?
Entera is a specialized biotechnology firm at the forefront of developing orally delivered macromolecules, including peptides and therapeutic proteins. The company addresses critical unmet medical needs by transforming injectable treatments into convenient, daily oral tablet formats. Its core pipeline features advanced candidates such as EB613 for high-risk post-menopausal osteoporosis and EB612 for hypoparathyroidism. By leveraging its unique delivery technology, Entera aims to redefine the standard of care for patients requiring chronic peptide replacement therapy, effectively bridging the gap between complex biological science and patient-centric therapeutic delivery.
How much funding has Entera raised?
Entera has raised a total of $282.5M across 2 funding rounds:
Debt
$7.5M
Stock/Share Issuance
$275M
Debt (2016): $7.5M with participation from Pontifax
Stock/Share Issuance (2026): $275M led by Driehaus Capital Management, TCG Crossover, Vivo Capital, BVF Partners, Perceptive Advisors, Catalio Capital Management, Logos Capital, RA Capital Management, Longitude Capital, and Venrock
Key Investors in Entera
Driehaus Capital Management
Founded in 1982 and headquartered in Chicago, Illinois, Driehaus Capital Management is a company that provides investment management services.
TCG Crossover
TCG Crossover is a science-driven investment firm focused on advancing disruptive medicines and supporting innovators in the pharmaceutical and biotechnology sectors.
Vivo Capital
Vivo Capital is a global healthcare investment firm founded in 1996, specializing in private and public equity as well as venture capital within the life sciences industry.
What's next for Entera?
With the recent influx of capital, Entera is strategically positioned to advance its lead clinical assets through critical regulatory milestones. The company's roadmap focuses on the successful execution of clinical trials for EB613 and EB612, aiming to demonstrate both safety and efficacy in larger patient populations. Furthermore, the firm is expected to leverage its strengthened financial position to optimize its manufacturing processes and explore potential partnerships that could enhance the commercial viability of its oral delivery platform. As the company transitions toward potential market entry, the focus will remain on rigorous clinical validation and the scaling of its proprietary technology to address broader therapeutic indications.
See full Entera company page
